Management of Vaginal Complaints: A Pilot Study Within a Practice-Based Research Network
Completed
Agency for Healthcare Research and Quality (AHRQ)
Early Phase 1
2007-02-01
Many women present in primary care with vaginal complaints. The best way of managing these
complaints is unclear. This trial will test two different methods of managing patients with
vaginal complaints. This is a pilot trial.
Clindamycin 300 mg Capsules in Healthy Subjects Under Fed Conditions
Completed
Teva Pharmaceuticals USA
Phase 1
2003-11-01
The objective of this study is to compare the rate and extent of absorption of clindamycin
300 mg capsules (test) versus Cleocin HCl (reference, administered as 1 x 300 mg capsule
under fed conditions.
Clindamycin 300 mg Capsules in Healthy Subjects Under Fasting Conditions
Completed
Teva Pharmaceuticals USA
Phase 1
2003-11-01
The objective of this study is to compare the rate and extent of absorption of clindamycin
300 mg capsules (test) versus Cleocin HCl (reference), administered as 1 x 300 mg capsule
under fasting conditions.
W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzo
Completed
GlaxoSmithKline
Phase 1
2010-05-06
This study was conducted to determine if the bioavailability of clindamycin and its
metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of
methylparaben. This study compared the investigational study product and 2 marketed products:
- CLN 1%-BPO 3% Gel (clindamycin 1%-BPO 3%), methylparaben-free
- Topical Gel (clindamycin 1%-BPO 5%), methylparaben-preserved (Topical Gel-MP)
- Once Daily Gel ((clindamycin 1%-BPO 5%), methylparaben-free (Topical Gel-MPF)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
